Sarepta said on Monday that its late-stage study testing two gene-targeted therapies for Duchenne muscular dystrophy did not ...
Sarepta said on Monday that its late-stage study testing two gene-targeted therapies for Duchenne muscular dystrophy did not ...
Investor's Business Daily on MSN
Sarepta Crashes After Two Muscular Dystrophy Drugs Fail Confirmatory Tests
Sarepta stock crashed late Monday after the biotech company said two of its muscular dystrophy drugs failed their ...
Shares of Sarepta Therapeutics Inc. plunged in extended trading Monday after the biotechnology company disclosed ...
Sarepta Therapeutics ( SRPT) shares fell after its late-stage trial for two gene therapies, AMONDYS 45 (casimersen) and VYONDYS 5 (golodirsen), aimed at treating Duchenne muscular dystrophy, did not ...
MedPage Today on MSN
Long-Term Givinostat Data Reinforce Safety Profile in Duchenne Muscular Dystrophy
Givinostat is an oral histone deacetylase (HDAC) inhibitor approved by the FDA in 2024 to treat Duchenne patients ages 6 ...
Publication highlights Deramiocel’s anti-fibrotic activity and describes a validated potency assay supporting quality control ...
His parents Stephen and Jenny have asked Sheffield Children's NHS Foundation Trust to approve the use of drug givinostat, ...
The Swiss pharma is paying $12 billion for Avidity Biosciences and its three late-stage antibody oligonucleotide conjugates.
Data from the Phase Ia/b study demonstrated that SAT-3247 was well-tolerated and safe with a desirable PK profile.
A San Diego community upgraded an adaptive van for Eddie Garcia, a boy with Duchenne Muscular Dystrophy, providing a motorized ramp to ease his mobility challenges.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback